IGC Pharma Inc
NYSE American:IGC

  • LAST PRICE
    0.5600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.5510/ 17
  • Ask / Lots
    0.5700/ 72
  • Open / Previous Close
    0.6100 / 0.5600
  • Day Range
    0.5300
    0.6200
  • 52 Week Range
    0.2501
    0.9099
  • Volume
    823,260

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 9, 2024

      Show headlines and story abstract

    • 8:45AM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: IGC

      May, 09, 2024 -- (IGC Pharma, Inc. (IGC)) --

      (NewsDirect)

      By Faith Ashmore, Benzinga

      Over 6.7 million Americans aged 65 and older are living with Alzheimer's disease (AD) and this number is predicted to grow to 13.8 million by 2060. AD is the sixth leading cause of death in the U.S. and in 2023, it was projected to cost the U.S. $345 billion. Alzheimer's disease is characterized by a gradual decline in memory, thinking, behavior and social skills; however, a lesser-known subsection of Alzheimer's patients -- despite a prevalence of 40%-80% in the patient population -- suffer from Agitation in Alzheimer's Disease (AAD). AAD is associated with higher admission rates to assisted living facilities, higher use of medications, higher rates of long-term hospitalizations and higher mortality rates for Alzheimer's patients. This brings a significant emotional and financial cost to patients and caregivers.

Peers Headlines